# DESTINY-Lung04 (NCT05048797)

> A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05048797
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Interventions: Trastuzumab Deruxtecan; Cisplatin; Carboplatin; Pembrolizumab; Pemetrexed
- Enrollment: 454
- Primary outcome: Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 47
- Podcasts: 31
- YouTube: 29
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=destiny-lung04-nct05048797

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05048797", "email": "<work email>"}; the inbox owner confirms by the emailed link.